## Mehmet Ã**‡**lan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5083417/publications.pdf

Version: 2024-02-01

		1163117	1058476	
16	204	8	14	
papers	citations	h-index	g-index	
16	16	16	359	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	Citations
1	Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome. Endocrine, 2016, 53, 271-279.	2.3	40
2	Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome. Clinical Endocrinology, 2016, 85, 910-917.	2.4	38
3	Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. Endocrine Research, 2017, 42, 145-153.	1.2	21
4	Increased circulating urocortin-3 levels is associated with polycystic ovary syndrome. Gynecological Endocrinology, 2016, 32, 218-222.	1.7	12
5	Increased circulating levels of irisin are associated with cardiovascular risk factors in subjects with acromegaly. Hormones, 2019, 18, 435-442.	1.9	12
6	The relationship of urotensin II with insulin resistance and hs-CRP in patients having PCOS. Gynecological Endocrinology, 2013, 29, 970-973.	1.7	10
7	A possible link between luteinizing hormone and macrophage migration inhibitory factor levels in polycystic ovary syndrome. Endocrine Research, 2016, 41, 261-269.	1.2	10
8	Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome. Endocrine, 2019, 65, 175-183.	2.3	10
9	Circulating insulin-like peptide 5 levels and its association with metabolic and hormonal parameters in women with polycystic ovary syndrome. Journal of Endocrinological Investigation, 2019, 42, 303-312.	3.3	9
10	Increased urocortin 3 levels are associated with the risk of having type 2 diabetes mellitus. Journal of Diabetes, 2020, 12, 474-482.	1.8	9
11	The relationship between urotensin II and insulin resistance in women with gestational diabetes mellitus. Hormones, 2019, 18, 91-97.	1.9	8
12	Relation of Decreased Circulating Sortilin Levels With Unfavorable Metabolic Profiles in Subjects With Newly Diagnosed Type 2 Diabetes Mellitus. American Journal of the Medical Sciences, 2020, 359, 8-16.	1.1	7
13	Association of kallistatin with carotid intima-media thickness in women with polycystic ovary syndrome. Minerva Endocrinology, 2018, 43, 236-245.	1.1	7
14	Association of decreased C1q/tumor necrosis factorrelated protein-5 levels with metabolic and hormonal disturbance in polycystic ovary syndrome. Journal of the Turkish German Gynecology Association, 2019, 20, 89-96.	0.6	6
15	Neudesin: a neuropeptide hormone decreased in subjects with polycystic ovary syndrome. Gynecological Endocrinology, 2020, 36, 849-853.	1.7	5
16	Correlation of serum C1q-tumour necrosis factor-related protein 5 levels with metabolic parameters and carotid intima-media thickness in newly diagnosed type 2 diabetes mellitus patients. Hormones, 2020, 19, 559-564.	1.9	0